Effect of daily administration period of natural α-interferon in patients with chronic hepatitis C

American Journal of Gastroenterology

Volumn 91, Issue 4, 1996, Pages 743-747

  Toyoda, Hidenori ^a   Nakano, Satoshi ^a   Kumada, Takashi ^a   Takeda, Isao ^a   Sugiyama, Keiichi ^a   Osada, Toshimasa ^a   Kiriyama, Seiki ^a  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; RNA, VIRAL; TIME FACTORS;

EID: 0029967851     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B, hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315:1575-8.
2. Jacyna MR, Brooks MG, Loke RHT, et al. Randomised controlled trial of interferon alpha (lymphoblastoid interferon) in chronic non-A, non-B hepatitis. Br Med J 1989;298:80-2.
3. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferin alpha: A multicenter randomized controlled trial. N Engl J Med 1989;321:1501-6.
4. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alpha therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-10.
5. Marcellin P, Boyer N, Giostra E, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France. Hepatology 1991;13: 393-7.
6. Saracco G, Rosina F, Torrani Cerenzia MR, et al. A randomized controlled trial of interferon alpha-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 1990;11:S43-9.
7. Ferenci P, Vogel W, Pristautz H, et al. One-year treatment of chronic non-A, non-B hepatitis with interferon alpha-2b. J Hepatol 1990;11: S50-6.
8. Weiland O, Schvarcz R, Wejstal R, et al. Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alpha-2b: Swedish experience. J Hepatol 1990;11:S57-62.
9. Gomez-Rubio M, Porres JC, Castillo I, et al. Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group. J Hepatol 1990;11:S63-7.
10. Realdi G, Diodata G, Bonetti P, et al. Recombinant human interferon alpha-2a in community-acquired non-A, non-B chronic active hepatitis: Preliminary results of a randomized, controlled trial. J Hepatol 1990;11:S68-71.
11. Saez-Royuela F, Porres JC, Moreno A, et al. High doses of recombinant alpha interferon or gamma interferon for chronic hepatitis C: A randomized controlled trial. Hepatology 1991;13:327-31.
12. Hoofnagle JH, Di Bisceglie AM, Shindo M. Antiviral therapy of hepatitis C - present and future. J Hepatol 1993;17:S130-6.
13. Shibata M, Morishima T, Kudo T, et al. Serum hepatitis C virus sequences in post-transfusion non-A, non-B hepatitis. Blood 1991;77: 1157-60.
14. Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers. An application to clinical surveys and tracing infection scores. J Gen Virol 1992;73: 673-9.
15. Simmonds P, Alberti A, Alter HJ, et al. A proposed system foe the nomenclature of hepatitis C viral genotypes. Hepatology 1994;19: 1321-4.
16. Hagiwara H, Hayashi N, Mita E, et al. Quantative analysis of hepatitis C virus in serum during interferon alpha therapy. Gastroenterology 1993;104:877-83.
17. Lau JYN, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-4.
18. Causse X, Goginot H, Chevallier M, et al. Comparizon of 1 or 3 MU interferon alpha-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497-502.
19. Hagiwara H, Hayashi N, Mita E, et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha. Hepatology 1992;15:37-41.
20. Chayama K, Saitoh S, Arase Y, et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1991;13:1040-3.
21. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with interferon. Hepatology 1992;15:1013-6.
22. Marcellin P, Pouteau M, Boyer N, et al. Retreatment with recombinant interferon-α in patients with chronic hepatitis C. J Infect Dis 1993; 167:780.
23. Marriott E, Quiroga JA, Carreno V. Retreatment of chronic hepatitis C with interferon-α. J Infect Dis 1992;166:1200-1.
24. Hoofnagle JH, Di Bisceglie AM. Treatment of chronic type C hepatitis with alpha interferon. Semin Liver Dis 1989;9:259-63.
25. Davis GL. Recombinant α-interferon treatment of non-A, non-B (type C) hepatitis: Review of studies and recommendations for treatment. J Hepatol 1990;11:S72-7.
26. Causse X, Godinot H, Ouzon D, et al. Recombinant alpha interferon for chronic non-A, non-B hepatitis: Optimal dose and factors associated with favourable response. J Hepatol 1989;10:643 (abstract).
27. Schvarcz R, Weiland O, Wejstal R, et al. A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: No correlation of outcome to presence of hepatitis C virus antibodies. Scand J Infect Dis 1989;21:617-25.
28. Hess G. Treatment of chronic hepatitis C. J Hepatol 1991;12:S17-20.
29. Shindo M, Di Bisceglie A, Cheung L, et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991;115:700-4.
30. Schlauder G, Leverenz G, Mattson L, et al. Detection of hepatitis C viral RNA by the polymerase chain reaction in serum of patients with post-transfusion non-A, non-B hepatitis. J Virol Methods 1992;37: 189-200.
31. Carreno V, Marriott E, Quiroga JA. Other approaches to the treatment of chronic viral hepatitis. J Hepatol 1993;17:S127-9.
32. Reichard O, Foberg U, Fryden A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α 2b for 60 weeks. Hepatology 1994;19:280-5.
33. Yoshioka K, Kakumu S, Wakita T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: Relationship to genotypes of hepatitis C virus. Hepatology 1992;16: 293-9.
34. Enomoto N, Takada A, Nakao T, et al. There are two major types of hepatitis C viruses in Japan. Biochem Biophys Res Commun 1990; 170:1021-5.
35. Takada N, Takase S, Enomoto N, et al. Clinical backgrounds of patients having different types of hepatitis C virus genomes. J Hepatol 1992;14:35-40.
36. Kanai K, Kato M, Okamoto H. HCV genotype in chronic hepatitis C and response to interferon. Lancet 1992;339:1543.
37. Orito E, Mizokami M, Nakano T, et al. Serum hepatitis C RNA level as a predictor of subsequent response to interferon-α therapy in Japanese patients with chronic hepatitis C. J Med Virol 1994; 44:410-4.